Patrys Ltd (PAB)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Patrys Ltd (PAB) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013562
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:28
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:オーストラリア
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Patrys Ltd (Patrys) is a healthcare company that provides therapeutic products. The company offers product pipeline such as PAT-SC1 used for the treatment of gastric cancer; PAT-SM6, PAT-PA1, and PAT-LM1 used to treat multiple cancers. It develops natural human antibody-based therapeutic products for the treatment of cancer and many other diseases. Patrys’ pipeline consists of antibodies at different stages of early preclinical development and library, consists of discoveries stage of anti-cancer natural human antibodies. The company distributes its products in the US, Japan, Canada, Australia; and in different parts of Europe, and others. Patrys is headquartered in Melbourne, Victoria, Australia.

Patrys Ltd (PAB) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Patrys Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Patrys Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Patrys Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Patrys Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Patrys Ltd, Medical Devices Deals, 2011 to YTD 2017 9
Patrys Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Patrys Ltd, Pharmaceuticals & Healthcare, Deal Details 11
Licensing Agreements 11
Patrys Enters into Licensing Agreement with Yale University 11
Patrys Enters into Licensing Agreement with Yale University 12
Hefei Co-source to Enter into Licensing Agreement with Patrys for PAT-SC1 13
Equity Offering 14
Patrys Completes Private Placement Of Shares For US$0.8 Million 14
Patrys Completes Rights Offering Of Shares 15
Patrys Completes Second Tranche Of Private Placement Of Shares For US$1 Million 16
Patrys Announces Rights Offering Of Shares For US$0.81 Million 18
Patrys Completed Private Placement Of Common Stock For US$3.48 Million 19
Patrys Ltd – Key Competitors 20
Patrys Ltd – Key Employees 21
Patrys Ltd – Locations And Subsidiaries 22
Head Office 22
Other Locations & Subsidiaries 22
Recent Developments 23
Product News 23
03/31/2016: Publication Highlights Role of Patrys’ DNA-Damaging Antibody 5-C6 in Cancer 23
03/31/2016: Publication Highlights Role of Patrys’ DNA-Damaging Antibody Deoxymab in Cancer 24
Clinical Trials 25
Sep 14, 2017: Patrys: PAT-DX1 Active in Pre-clinical Cancer Models 25
Apr 19, 2017: Deoxymab 3E10 lead candidate confirmed 26
Other Significant Developments 27
May 01, 2017: Patrys provides Finance Update 27
Appendix 28
Methodology 28
About GlobalData 28
Contact Us 28
Disclaimer 28

List of Tables
Patrys Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Patrys Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Patrys Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Patrys Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Patrys Ltd, Deals By Therapy Area, 2011 to YTD 2017 8
Patrys Ltd, Medical Devices Deals, 2011 to YTD 2017 9
Patrys Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Patrys Enters into Licensing Agreement with Yale University 11
Patrys Enters into Licensing Agreement with Yale University 12
Hefei Co-source to Enter into Licensing Agreement with Patrys for PAT-SC1 13
Patrys Completes Private Placement Of Shares For US$0.8 Million 14
Patrys Completes Rights Offering Of Shares 15
Patrys Completes Second Tranche Of Private Placement Of Shares For US$1 Million 16
Patrys Announces Rights Offering Of Shares For US$0.81 Million 18
Patrys Completed Private Placement Of Common Stock For US$3.48 Million 19
Patrys Ltd, Key Competitors 20
Patrys Ltd, Key Employees 21
Patrys Ltd, Subsidiaries 22

★海外企業調査レポート[Patrys Ltd (PAB)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Corvia Medical Inc-医療機器分野:企業M&A・提携分析
    Summary Corvia Medical Inc (Corvia), formerly DC Devices Inc is a medical device company that offers structural heart disease solutions. The company develops interatrial shunt device (IASD), a trans-catheter device designed diastolic heart failure, also known as heart failure with preserved ejection …
  • My Health Direct Inc:医療機器:M&Aディール及び事業提携情報
    Summary My Health Direct Inc (MHD) is a healthcare technology company that offers web-based solutions for the management of healthcare appointments. The company helps clients in achieving incremental revenue growth and real-time cost containment savings. It offers products such as consumer direct an …
  • IMPACT Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary IMPACT Therapeutics Inc (IMPACT) is a developer of therapeutics to treat cancer and other life-threatening diseases. The company provides products such as microtubule inhibitors, PARP-1 inhibitors, and Hedgehog pathway inhibitors for oncology. Its PARP-1 inhibitor is an oral bioavailability; …
  • Fujirebio Europe NV:企業の戦略的SWOT分析
    Fujirebio Europe NV - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • genOway SA (ALGEN):製薬・医療:M&Aディール及び事業提携情報
    Summary genOway SA (genOway) is a biotechnology company that develops genetically modified mouse, rat and cellular models for pharmaceutical companies and research institutes. The company develops several technology platforms such as safe DNA transgenesis, quick knock-in, safe in vivo RNAi and safe …
  • Max Delbruck Center for Molecular Medicine:製薬・医療:M&Aディール及び事業提携情報
    Summary Max Delbruck Center for Molecular Medicine (MDC) is a biomedical research center that offers translating discoveries from molecular research into applications. The company’s research area services offer for cancer research, cardiovascular and metabolic disease, diseases of the nervous system …
  • Omega Protein Corporation:企業の戦略・SWOT・財務分析
    Omega Protein Corporation - Strategy, SWOT and Corporate Finance Report Summary Omega Protein Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • JBS S.A.:企業のM&A・事業提携・投資動向
    JBS S.A. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's JBS S.A. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital …
  • Genmedica Therapeutics SL:製薬・医療:M&Aディール及び事業提携情報
    Summary Genmedica Therapeutics SL (Genmedica) is a clinical-stage biopharmaceutical company that researches, discovers and develops orally available NCEs for the treatment of diabetes. The company’s expertise spans provides development of specific, dual-action, small molecule inhibitors that targets …
  • Lipocine Inc (LPCN):企業の財務・戦略的SWOT分析
    Summary Lipocine Inc (Lipocine) operates as a pharmaceutical company that develops and commercializes treatment for men's and women's health. The company’s pipeline products for men’s health include LPCN 1111 and LPCN 1021; and for women’s health include LPCN 1107. Its LPCN 1111 is an oral testoster …
  • Rada Electronic Industries Ltd.:企業の戦略・SWOT・財務分析
    Rada Electronic Industries Ltd. - Strategy, SWOT and Corporate Finance Report Summary Rada Electronic Industries Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Xylem Inc (XYL):企業の財務・戦略的SWOT分析
    Xylem Inc (XYL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • PipeHawk Plc:企業の戦略・SWOT・財務分析
    PipeHawk Plc - Strategy, SWOT and Corporate Finance Report Summary PipeHawk Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • EVN AG (EVN):企業の財務・戦略的SWOT分析
    EVN AG (EVN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pote …
  • Laboratorios Farmaceuticos Rovi SA (ROVI):企業の財務・戦略的SWOT分析
    Summary Laboratorios Farmaceuticos Rovi SA (Rovi) is a pharmaceutical company engaged in the research, development, manufacturing, and marketing of prescription and hospital products. The company's product portfolio includes licensed prescription pharmaceuticals in the therapeutic areas of cardiovas …
  • New Carolin Gold Corp:企業の戦略・SWOT・財務情報
    New Carolin Gold Corp - Strategy, SWOT and Corporate Finance Report Summary New Carolin Gold Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Scomi Group Bhd (SCOMI):企業の財務・戦略的SWOT分析
    Scomi Group Bhd (SCOMI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Cholamandalam Investment and Finance Company Ltd (CHOLAFIN):企業の財務・戦略的SWOT分析
    Cholamandalam Investment and Finance Company Ltd (CHOLAFIN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the comp …
  • Precision Biosciences Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Precision Biosciences Inc (Precision BioSciences) is a biotechnology company, which develops and commercializes gene therapy and cancer immunotherapy. The company focuses its ARCUS technology, a proprietary genome editing platform, which combines specificity and efficacy, on the development …
  • Knoll Inc (KNL):企業の財務・戦略的SWOT分析
    Knoll Inc (KNL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆